Our findings indicate that potentiating the activity of NGF at the level of RhoA inactivation and PTP1B activation may represent a new means to combat the noxious effects of Aβ in Alzheimer's disease. This evidence concerns the gene PTPN1 and early-onset autosomal dominant Alzheimer disease.